An interventional study of Inhaled anaesthetic agent in Ischemic Heart Disease, sponsored by Region Skane. Completed at 1 site in Sweden. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2015-05-14.
Sponsored by Region Skane · Not applicable, Interventional, and Basic science
The purpose is to investigate how the adsorptive capacity of the active carbon filter to carbon dioxide in an anaesthetic gas reflector (AnaConDa) is affected by adding inhaled anaesthetic agent.
The hypothesis is that addition of inhaled anaesthetic agent will affect the amount of adsorption of carbon dioxide to the active carbon and thereby affect rebreathing of carbon dioxide.
3,639 studies on the registry are indexed under Heart Diseases; 461 are open to participants now.
This study's enrollment of 12 is below the median of 100 across 1,778 interventional studies indexed under Heart Diseases.
Browse Heart Diseases studies →Region Skane is the lead sponsor of 372 studies on the registry; 113 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
The group where the investigators adds inhaled anaesthetic agent when using the anaesthetic gas reflector (AnaConda).
Other: Inhaled anaesthetic agent
Volume of carbon dioxide rebreathing from an anesthetic gas reflector
Tidal carbon dioxide volume rebreathed from an anesthetic gas reflector correlated to concentration of delivered anesthetic gas.
Time frame: 2 hours
Quantification of ventilatory requirements to maintain isocapnia with the use of an anesthetic gas reflector.
Changes of tidal volume required to maintain constant alveolar ventilation will be assessed by continuous measurement of exhaled tidal carbon dioxide volume, the latter to be maintained at a constant value.
Time frame: 2 hours
This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Region Skane